What Дезринит Treats: Main Uses and Benefits

The therapeutic use of Mometasone Furoate focuses on addressing symptoms related to inflammatory or irritative states. This medication is commonly used to provide anti-inflammatory support to the nasal lining. This support is generally relevant in clinical presentations marked by persistent or heightened nasal symptoms driven by inflammation.

It is applied across therapeutic domains where additional symptomatic support is needed, primarily for conditions involving seasonal and perennial allergic rhinitis, and the management of nasal polyps. This medication helps address symptom clusters that may become intense or disruptive, such as recurrent sneezing, persistent nasal itching, excessive discharge, and physical congestion.

In clinical scenarios, it is often used during phases when symptoms become more noticeable, providing supportive relief when symptoms interfere with routine activities. It assists with maintaining functional stability and addressing symptoms linked to organ-specific functional stress, easing discomfort in conditions where functional stability becomes affected.

---

Quick Fact: Therapeutic Support

This medication is commonly used to ease the effects of chronic swelling in the nasal tissues, which is relevant for managing nasal congestion, and contributes to the overall symptom load reduction during symptomatic periods.

Who Can and Cannot Use Дезринит?

The eligibility for using Дезринит (Mometasone Furoate nasal spray) is strictly defined by regulatory bodies based on age, clinical history, and specific conditions. This information reflects official governmental labeling.

Eligibility Summary

Population Category	Regulatory Status	Key Constraint
Allergic Rhinitis	Approved for Adults and Adolescents (12 years and older).	Approved for Children (3 to 11 years).
Nasal Polyps	Approved for Adults only (18 years and older).	Safety and efficacy not established in patients under 18.
Pregnancy/Lactation	Conditional Use.	Use only if potential benefit justifies potential risk.

---

Absolute Restrictions (Contraindications)

The medicine must not be used by specific patient groups to avoid serious risk or interference with healing:

• Hypersensitivity: Patients with a known allergy to mometasone furoate or any other component in the formulation.
• Nasal Trauma/Surgery: Use is prohibited until complete healing has occurred following recent nasal surgery or nasal trauma.
• Infection: Patients with an untreated localized infection involving the nasal mucosa, such as ocular herpes simplex, must not use the spray.

Patients with active or quiescent tuberculosis or other untreated systemic infections (e.g., fungal, bacterial, or viral) require great caution, and use must be determined based on a benefit-risk assessment.

Interactions with other medicines and products: Official Regulatory Information

The interaction profile for Дезринит (Mometasone Furoate nasal spray) primarily addresses effects on systemic exposure, as documented by regulatory authorities. The nasal route of administration and generally low systemic absorption limit the number of documented drug-drug interactions.

Pharmacokinetic Interaction and Restriction

Classification	Interacting Substance Category	Regulatory Constraint
Metabolic Clearance	Strong Cytochrome P450 3A4 (CYP3A4) Inhibitors	Co-administration should be avoided unless potential benefits outweigh the increased risk.

Co-administration with Strong CYP3A4 Inhibitors has the potential to inhibit the metabolism and subsequent clearance of Mometasone Furoate. This inhibition may lead to increased systemic exposure of the corticosteroid and a corresponding elevated risk of systemic corticosteroid side-effects, a finding officially noted in prescribing information.

Absence of Documented Interactions

Clinical studies have formally confirmed that no interaction was observed between Mometasone Furoate nasal spray and the specific antihistamine Loratadine. Furthermore, official regulatory documents do not contain explicit details regarding clinically significant interactions with food, alcohol, or commonly used herbal products.

Mechanism of Action: Mometasone Furoate

The action of mometasone furoate is highly localized, targeted to the nasal mucosa, and mediated by its interaction with the intracellular glucocorticoid receptor (GR).

This drug-receptor complex translocates to the cell nucleus where it modulates gene transcription. This mechanism engages specific pathways, promoting the synthesis of anti-inflammatory proteins while suppressing the genes responsible for producing pro-inflammatory mediators, including various cytokines, chemokines, prostaglandins, and leukotrienes.

This broad cascade modulation leads to a decrease in the activity and accumulation of key immune cells, such as eosinophils and mast cells, within the tissue. By altering the signaling dynamics that may escalate under certain conditions, the mechanism results in adjustments to the localized physiological state that characterize the observed modulation of inflammation.

How to Use Дезринит: Administration Guidelines

Дезринит (Mometasone Furoate) is supplied as an aqueous nasal spray suspension intended exclusively for intranasal use. All administration protocols and dosages are defined to ensure the correct amount of the 50 mu g dose is delivered per metered spray.

---

Administration Preparation

The nasal spray container must be shaken well before each use. Before the initial use, the device requires 10 actuations (priming) to ensure a uniform spray. If the device remains unused for 14 days or longer, it must be reprimed with two actuations before the next administration.

---

Labeled Dosing Regimens

Indication	Age Group	Standard Regimen	Total Daily Dose	Maximum Frequency
Allergic Rhinitis	Adults/Adolescents (ge 12 years)	2 sprays per nostril once daily	200 mu g	Once daily
Allergic Rhinitis	Children (3–11 years)	1 spray per nostril once daily	100 mu g	Once daily
Nasal Polyps	Adults (ge 18 years)	2 sprays per nostril once daily (starting)	200 mu g	Twice daily

---

Administration Protocol Principles

Treatment for seasonal allergic rhinitis may be initiated 2 to 4 weeks prior to the anticipated start of the pollen season. For all indications, guidelines direct that the dose should be titrated down to the lowest amount that effectively maintains symptom control. Furthermore, the product must be discarded 2 months after the first use or after the labeled number of sprays has been dispensed, whichever comes first. Safety and efficacy for the treatment of nasal polyps are not established in patients under 18 years of age.

Research Evidence / Overview of Studies

Global Efficacy and Safety Profile

A number of controlled studies and systematic reviews have evaluated the compound as a research candidate for managing inflammatory conditions of the nose and sinuses in adult participants. Researchers investigated endpoints related to certain inflammatory markers across different patient populations.

The compound was the subject of research for managing both acute flare-ups and long-term symptom protocols. Research has focused on the compound's effect on certain biological markers related to the body's inflammatory response.

Key Study Findings

Studies have examined the use of the compound in various stages of allergic rhinitis, including both seasonal and perennial forms. One major trial investigated measuring changes in participant symptoms of 400 individuals over a 12-week period.

• The primary endpoint of this trial was the evaluation of changes in the total nasal symptom severity scoring system after 12 weeks.
• Secondary endpoints included assessing participant-reported quality of life.

Study protocols generally focused on a low dose administered to participants, such as 200 mcg once daily. Other research has focused on pharmacokinetics, looking at how the body processes the compound.

Combination Use and Future Directions

Some early-phase research has explored the use of the compound alongside standard agents. These studies assessed endpoints related to patient well-being and levels of disease activity over a period of 6 months. The findings from these exploratory studies explored the timeline of changes, without comparison to other treatments.

Key Studies & References

1. Study to Compare the Pharmacokinetics of Fixed-Dose Combination of Mometasone + Azelastine Nasal Spray to Mometasone and Azelastine Nasal Sprays in Adolescents and Young Adults With Seasonal Allergic Rhinitis (ClinicalTrials.gov)

Common questions about Дезринит (FAQ)

Q: Is Дезринит an antibiotic or an antihistamine?

A: Дезринит (mometasone) is a corticosteroid (often called a steroid) and is applied directly to the nasal passages. It is not an antibiotic, which treats bacterial infections, nor is it an antihistamine, which blocks histamine action.

Q: How quickly does Дезринит start to work?

A: The official product information suggests that the full benefit of Дезринит may not be experienced immediately. Consistent, regular use over several days to a week may be necessary before an individual notices the maximum therapeutic effect.

Q: Is it safe to use Дезринит every day?

A: The duration and frequency of use, including whether it should be used every day, should be determined by a healthcare provider. The official guidance typically involves using the medication as prescribed for the indicated duration.

Q: Can children use Дезринит?

A: Use in children is typically based on the specific product label and the child’s age, which varies by indication and country. It is important to confirm with a doctor if this product is appropriate for use in a child and to follow their instructions precisely.

Storage and Disposal of Дезринит

Storage and disposal of this product must strictly comply with the requirements detailed in official regulatory documentation.

---

Storage Requirements

• Temperature Restrictions: The medicine must be stored at temperatures not above 30°C and must be kept away from heat.
• Freezing Prohibition: It is a mandatory instruction to not freeze the product.
• Child Safety: The nasal spray must be kept out of the sight and reach of children to prevent accidental access.

---

Stability and Disposal Rules

• Post-Opening Stability: To ensure quality, the nasal spray bottle must be discarded within 2 months of first use.
• Unopened Shelf-Life: The product's shelf life is typically 2 years prior to first opening.
• Disposal: Any unused medicine or waste material must be disposed of in accordance with local requirements for pharmaceutical products.